Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma.
Dr Sommerville was VP, clinical sciences, at Pfizer for three years having joined the company from King Pharmaceuticals.
At GW he will assume in the newly-created role of VP, clinical research, where he will lead clinical development, medical affairs, and regulatory activities related to the company’s work in epilepsy, pain and other diseases.
GW’s research is focused on the development of cannabinoids. This includes Sativex, which became the world’s first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis in Canada and the European Union in 2010. It is also in clinical trials for other indications, including cancer pain.
“This is an exciting time to be joining GW, with a number of important products currently under development for patients in the US including Sativex and Epidiolex,” said Dr Sommerville.